February 2017 Vol 10, No 1
KLAS holds an annual event that brings together vendors and customers on neutral territory to improve the quality of offerings in the healthcare marketplace. Admittedly, this is an unusual methodology, and I was asked to set the intellectual table for this important event that was focused on population health.
Comparing Healthcare Costs Associated with Oral and Subcutaneous Methotrexate or Biologic Therapy for Rheumatoid Arthritis in the United States
Joseph Lee, PhD, Ryan Pelkey, MS, Julieanna Gubitosa, BS, Michael F. Henrick, MBA, Michael L. Ganz, PhD
Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis in adults, with a prevalence of approximately 0.6% in the United States. RA has a significant negative impact on health-related quality of life and imposes a substantial economic burden on the US healthcare system.
Identifying the Most Clinically and Economically Effective Therapies for Rheumatoid Arthritis Remains a Challenge for Providers and Payers
Sociodemographic Determinants of Out-of-Pocket Expenditures for Patients Using Prescription Drugs for Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory disease that is typically accompanied by swelling, tenderness of the joints, and destruction of the synovial joints. The progression of RA can cause disability and can have serious physical, mental, and economic consequences for patients.
Understanding Patients’ Demographics Is Key to Improving Clinical and Economic Healthcare Outcomes
Pharmaceutical Patent Litigation and the Emerging Biosimilars: A Conversation with Kevin M. Nelson, JD
Biologic Disease-Modifying Antirheumatic Drugs in a National, Privately Insured Population: Utilization, Expenditures, and Price Trends
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease of unknown cause that primarily affects the peripheral joints in a symmetric pattern. RA’s effect on other areas of the body, including the skin, heart, lungs, and eyes, can be substantial.
Rheumatoid Arthritis, Biologic Drugs, and Associated Cost
The year 2016 saw a “pause” in most market trends as the US presidential election cycle unfolded and Brexit occurred. As we begin 2017 with a new Republican leadership in Washington, DC, led by outsider President Donald Trump, we know that change is imminent throughout all segments of the US market.
Results 1 - 6 of 6